This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Amy Lugo, PharmD
Advertisement
Articles by Amy Lugo, PharmD
Advertisement
Latest Updated Articles
- Cost-effectiveness of Diabetes Treatment Sequences to Inform Step Therapy Policies
Published: March 10th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
4
Key Federal Legislation Impacting Managed Care Pharmacy: Geni Tunstall, JD
5
